Dataset Information

Transcriptome analysis of KRT15 knockdown in lenvatinib-resistant papillary thyroid carcinoma cells

ABSTRACT: Lenvatinib resistance is a major clinical obstacle in the treatment of radioiodine-refractory papillary thyroid cancer (PTC), and clarifying its molecular mechanisms is crucial for developing effective therapeutic strategies. In this study, we identify Keratin 15 (KRT15) as a key driver of this resistance. We found that KRT15 overexpression is associated with an unfavorable clinical prognosis in PTC patients. Mechanistically, KRT15 interacts with Keratin 81 (KRT81) to form a regulatory complex that upregulates Diacylglycerol Kinase B (DGKB). This KRT15-KRT81-DGKB axis drives metabolic reprogramming by increasing the expression of key fatty acid oxidation (FAO) enzymes, such as CPT1A and ACOX1, which enhances cellular energetics and promotes survival under therapeutic stress. Consequently, inhibition of this pathway successfully resensitizes resistant cells to lenvatinib. Taken together, our study reveals a novel mechanism where cytoskeletal proteins mediate metabolic adaptation in drug-resistant PTC cells, identifying the KRT15-KRT81-DGKB pathway as a promising therapeutic target to overcome lenvatinib resistance in refractory PTC patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE299763 | GEO | 2026/06/18

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Abstract: Cancer-associated fibroblasts (CAFs) play an important role in the induction of chemo-resistance. The objectives of this study were to clarify the mechanism underlying CAF-mediated sorafenib/lenvatinib resistance and identify a novel therapeutic target to overcome resistance to sorafenib/lenvatinib in hepatocellular carcinoma (HCC). Methods: Whole transcriptome sequencing (WTS) data of nine pairs of CAFs and para-cancer-associated fibroblasts (PAFs) were analyzed to identify key molecules that induce resistance to tyrosine kinase inhibitors (TKIs). In vitro and in vivo experiments were performed to validate selected targets and related mechanisms. Plasma secreted phosphoprotein 1 (SPP1) expression levels prior to sorafenib/lenvatinib treatment as well as progression-free survival (PFS) and overall survival (OS) of an advanced HCC cohort (n=42) were evaluated using Kaplan–Meier analysis. Results: Co-culturing CAFs and HCC cells significantly reduced the responsiveness of HCC cells to sorafenib/lenvatinib, in vitro and in vivo. Systematic integrative analysis of the WTS data of CAFs/PAFs and publicly available gene expression data indicated that CAF-derived SPP1 (CAF-SPP1) was suitable for use as a candidate molecule to induce sorafenib/lenvatinib resistance. An evaluation of the mechanisms involved indicated that CAF-SPP1 increased phosphorylation of PKCɑ, which then activated rapidly accelerated fibrosarcoma (RAF)-extracellular signal-related kinase 1/2-signal transducer and activator of transcription 3 (STAT3) and phosophoinositide 3-kinase (PI3K)-AKT-mechanistic target of rapamycin kinase (mTOR) in HCC cells. SPP1 inhibitors reversed CAF-induced sorafenib/lenvatinib resistance in vitro and in vivo. Patients showing high plasma SPP1 prior to sorafenib/lenvatinib treatment exhibited significantly poor PFS (P=0.005) and OS (P=0.041). Conclusions: CAF-SPP1 enhances sorafenib/lenvatinib resistance in HCC by alternatively activating oncogenic pathways via PKCɑ phosphorylation. Inhibition of CAF-SPP1 may be utilized as a therapeutic strategy against TKI resistance in HCC. Plasma SPP1 level prior to TKI treatment shows potential as a promising biomarker for predicting sorafenib/lenvatinib response in advanced HCC patients.

Dataset Information

Transcriptome analysis of KRT15 knockdown in lenvatinib-resistant papillary thyroid carcinoma cells

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets